drugset / Trial / NCT01896700

Methylphenidate to Improve Balance and Walking in MS

NCT01896700

RandomizedParallel-groupDouble-blindTreatment

Summary

Methylphenidate is an amphetamine-like psychomotor stimulant drug currently approved for the treatment of attention-deficit hyperactivity disorder (ADHD), postural orthostasis tachycardia syndrome and narcolepsy. It is also often prescribed off label to people with MS to improve fatigue. It is proposed that methylphenidate may also improve imbalance and walking deficits in MS by improving concentration and central integration, one of the primary mechanisms thought to underlie imbalance and walking deficits in MS.

Timeline

Start
2013-07
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 60 mg Oral

Indications